[Cholagogic effect of trimethylglycine in normal animals of different ages and in experimental atherosclerosis]. / Zhelchegonnyi éffekt trimetilglitsina u zhivotnykh raznogo vozrasta v norme i pri éksperimental'nom ateroskleroze.

Trimethylglycine at a dose of 1.5 g/kg was found to produce marked bile secretory effect in young and old rats. In rabbits with experimental atherosclerosis, trimethylglycine increased the content of biliary acids in the bile and normalized the indexes of lipid metabolism in the blood serum. Apparently, the effect on cholesterol transformation into biliary acids and its excretion with the bile is one of the mechanisms of anti-atherosclerotic action of trimethylglycine.

[Corrective effect of trimethylglycine on the nicotinamide coenzyme and adenine nucleotide content of the tissues in experimental atherosclerosis]. / Korrigiruiushchee vliianie trimetilglitsina na soderzhanie nikotinamidnykh kofermentov i adeninnukleotidov v tkaniakh pri éksperimental'nom ateroskleroze.

Experiments on adult rabbits with experimental atherosclerosis induced by cholesterol (0.25 g/kg for 90 days) showed that chronic administration of trimethylglycine (1.5 g/kg for 30 days) prevented a decrease of the liver and myocardium content of nicotinamide coenzymes and adenine nucleotides.

[Age-related characteristics of potassium glutamate pharmacokinetics]. / Vozrastnye osobennsoti farmakokinetiki kaliia glutaminata.

Experiments on young and old rabbits and rats were made to study the age-associated features of the pharmacokinetics of a new drug--potassium glutamate developed at the Laboratory of Experimental Pharmacology, Institute of Gerontology, Academy of Medical Sciences of the USSR. The age-associated differences in some pharmacokinetic parameters of potassium glutamate were disclosed: an increase in the half-life, a decrease in the overall clearance and a reduction in the elimination coefficient, an increase in the extent of distribution and area of the pharmacokinetic curve in old animals. A correlation was found between the pharmacokinetic parameters and drug pharmacological activity in animals of different age groups. The use of the pharmacokinetic data made it possible to calculate the optimal doses and to develop the schemes of effective application of potassium glutamate for young and old animals, as well as to extrapolate the experimental data to the drug clinical trials.

[Effect of trimethylglycine on lipid metabolism in experimental atherosclerosis in rabbits]. / Vliianie trimetilglitsina na lipidnyi obmen pri éksperimental'nom ateroskleroze u krolikov.

It has been shown in adult rabbits aged 8 months with experimental cholesterol atherosclerosis that administration of trimethylglycinee in a dose of 0.5 g/kg reduces the elevated content of total and ester-bound cholesterol, beta-lipoproteins, total lipids in the blood serum and that of total cholesterol and triglycerides in the liver. Little toxicity and high efficacy of trimethylglycin in experimental atherosclerosis make this compound prospective in the light of its use as an antisclerotic agent.

[Effect of potassium glutamate on the manifestation of experimental arrhythmias in rabbits]. / Vliianie kaliia glutaminata na proiavleniia éksperimental'nykh aritmii u krolikov.

In rabbits and rats potassium glutaminate elicits antiarrhythmic effect in experimental arrhythmias induced by intravenous injection of strophanthine and calcium chloride, normalizes the content of electrolytes (potassium, sodium, calcium, magnesium) in the myocardium and blood of animals after they are injected strophanthine.

[Antianemic effect of ampevit and orkomin]. / Antianemicheskii éffekt ampevita i orkomina.

The antianemic action of ampevit and orkomin developed at the Laboratory of Experimental Therapy, Institute of Gerontology, Academy of Medical Sciences of the USSR was studied in experiments on young and old animals. It has been established that repeated administration of the drugs increases the reticulocyte count in both groups of animals. Ampevit diminishes severity of posthemorrhagic anemia. Both drugs promote more rapid recovery of hemoglobin content and red cell count in old animals after blood loss. The data obtained were supported by clinical trials of the drugs which have been recommended for combined treatment of posthemorrhagic anemias and other conditions accompanied by weakened function of the growing red fiber of the bone marrow seen also in people of old and senile age.